ciglitazone has been researched along with Respiratory Syncytial Virus Infections in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Respiratory Syncytial Virus Infections: Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, R | 1 |
| Neumann, M | 1 |
| König, W | 1 |
1 other study available for ciglitazone and Respiratory Syncytial Virus Infections
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells.
Topics: Amino Acids; Cell Adhesion; Cell Line; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; | 2007 |